Welcome to our dedicated page for Usana Health Sciences SEC filings (Ticker: USNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
USANA Health Sciences, Inc. (NYSE: USNA) files a range of documents with the U.S. Securities and Exchange Commission that provide detail on its nutrition-focused business, financial condition, and governance. This page centralizes those SEC filings and pairs them with AI-powered summaries to help readers interpret the information more efficiently.
USANA’s current reports on Form 8-K include disclosures about preliminary financial results, updated net sales guidance, and leadership transitions, such as changes in the Chief Executive Officer role. Other 8-K filings describe credit agreements, financial covenants, and the posting of Management Commentary documents and conference call details related to quarterly results. These filings complement the company’s earnings releases and provide context on how management views performance in its direct selling and direct-to-consumer segments.
Investors can also use this page to access USANA’s periodic reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q, where available. These documents typically contain segment information, risk factor discussions, and explanations of non-GAAP measures such as Adjusted EBITDA and Adjusted diluted earnings per share, which USANA references in its communications.
Stock Titan’s platform enhances these filings with AI-generated highlights that explain key sections, summarize complex tables, and surface notable items such as changes in outlook, capital structure, or significant agreements. Users can quickly locate information on topics like net sales trends, credit facilities, or integration costs related to acquisitions such as Hiya, and can review insider-related disclosures when Forms 3, 4, or 5 are filed. Real-time updates from EDGAR help ensure that new USANA filings appear promptly with concise explanations.
USANA Health Sciences (USNA) – Form 4 insider filing: Director Peggie Pelosi reported RSU vesting and related share withholding on 24 Jul 2025. She converted 1,058 restricted stock units (code “M”), adding the same number of common shares at a $0 exercise price. To cover taxes, 606 shares were withheld/sold (code “F”) at $32.09, leaving a net increase of 452 shares.
Following the transactions, Pelosi now directly owns 4,135 common shares and still holds 3,172 un-vested/vested RSUs. No open-market purchases or discretionary sales were disclosed; the activity reflects scheduled equity compensation vesting. No changes to company guidance, operations, or financial metrics were included.
On 07/24/2025, USANA Health Sciences (USNA) director Frederic J. Winssinger filed a Form 4 showing the conversion of 1,058 restricted stock units (transaction code “M”) into the same number of common shares. The move increased his directly held common stock to 6,929 shares, up from 5,871, an 18% rise. No shares were sold.
Winssinger still owns 3,172 RSUs that vest in four equal 25 % tranches on 24 Jul 2025, 23 Oct 2025, 22 Jan 2026 and 23 Apr 2026. The filing lists a zero exercise price, typical for RSU settlement, and contains no additional corporate events or financial data. While modest, an insider increasing holdings is generally viewed as a constructive signal rather than a liquidity event.
USANA Health Sciences (USNA) – Form 4 filed 07/28/2025. Director Timothy E. Wood reported transactions dated 07/24/2025 involving restricted stock units (RSUs) and common shares.
- RSU exercise (Code M): 1,058 RSUs converted into an equal number of common shares at a stated price of $0.
- Disposition for tax withholding (Code F): 265 shares sold at $32.09 per share.
After the transactions Wood now directly owns 8,235 common shares. He also retains 3,172 unvested RSUs that convert 25 % on 07/24/2025, 10/23/2025, 01/22/2026, and 04/23/2026.
The filing reflects a net increase of 793 shares in Wood’s direct equity position and provides updated ownership data but does not contain company-level financial results or forward-looking statements.